Valuation: Polaris Group

Market Cap 7.18B 220M 197M 182M 165M 308M 20.92B 313M 2.19B 866M 10.96B 827M 809M 34.55B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 7.7B 236M 211M 195M 177M 330M 22.42B 336M 2.34B 928M 11.75B 886M 868M 37.04B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day-1.59%
1 week-4.04%
Current month-13.45%
1 month-19.09%
3 months-33.11%
6 months-54.00%
Current year-74.19%
1 week 15.3
Extreme 15.3
16.15
1 month 15.3
Extreme 15.3
18.35
Current year 15.3
Extreme 15.3
69.2
1 year 15.3
Extreme 15.3
70.64
3 years 15.3
Extreme 15.3
157.65
5 years 15.3
Extreme 15.3
446.58
10 years 15.3
Extreme 15.3
446.58
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%-4.04%-77.80%-89.15% 220M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.09%+1.77%+35.49%+117.88% 38.33B
Weighted average by Cap. +0.39%+2.73%+45.95%+142.70%

Financials

2024 2025
Net sales 107M 3.28M 2.93M 2.71M 2.45M 4.59M 312M 4.67M 32.59M 12.9M 163M 12.32M 12.06M 515M 40.6M 1.25M 1.11M 1.03M 931K 1.74M 118M 1.77M 12.37M 4.9M 61.95M 4.67M 4.58M 195M
Net income -2.5B -76.78M -68.56M -63.34M -57.4M -107M -7.29B -109M -762M -302M -3.82B -288M -282M -12.04B -3.93B -120M -108M -99.39M -90.07M -169M -11.44B -171M -1.2B -474M -5.99B -452M -443M -18.89B
Net Debt 9.19M 282K 252K 233K 211K 394K 26.77M 401K 2.8M 1.11M 14.03M 1.06M 1.04M 44.22M 517M 15.86M 14.16M 13.08M 11.86M 22.18M 1.51B 22.55M 157M 62.32M 789M 59.51M 58.25M 2.49B
Projected Income Statement - Annual - Polaris Group
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
22/10/26 NT$15.45 -1.59% 243,873
21/10/26 NT$15.70 +1.29% 225,085
20/10/26 NT$15.50 -0.32% 406,414
19/10/26 NT$15.55 -3.42% 352,353
16/10/26 NT$16.10 +1.26% 248,583
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock